Dallas, Texas 12/09/2013 (Financialstrend) – The last trading session witnessed a surprise when there was a sudden increase in the Keryx Biopharmaceuticals (NASDAQ:KERX) options volumes. There was a new record 90-day call record established for the traded contracts. For every put there were 1.8calls that were traded which yielded a 0.56 put/call ratio.
All these transactions are clear cut indicator that traders are trying hard to rebalance their portfolios and anticipating a price shift. Moreover sudden unusual increase in the volume activity also directly reflects towards investor’s outlook and it is a strong confirmation that the stock movement cannot be stooped, it is imminent.
As per the charts the Keryx is trading higher than the 200 day average and more than its 50 day average. During the market session the share price of Keryx opened at $14.56 but slipped downwards to $12.94. This range bound movement is also a clear cut indication that punters are trying to make money by exiting the stock and then re-entering it at a lower value.
What does Keryx exactly do?
Keryx Biopharmaceuticals (NASDAQ:KERX) is currently focusing on development, acquisition and commercialization of many medically important and urgent medical products and sincerely wants to answer the undeserved needs.
Under its current developmental program Keryx is trying to develop and investigate ferric citrate, oral compound that can bind with phosphate. As per the scientists this compound has the potential to treat hyperphosphatemia which is a common problem with Chronic Kidney disease patients. The company has also successfully completed a US Based 3 phase Clinical program with ferric citrate and followed all the protocols that were set by the US FDA.
All these new and latest clinical trials are also benefitting the company in big manner and its share value is witnessing an increasing trend and 2014 is going to be an exciting new year for the company.